Menu
Log in
Forgot password
Log in
Forgot password

News

  • Home
  • Resources
  • Literature Updates
  • Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer

18 Jul 2025 11:49 AM | Anonymous member (Administrator)

Hisato Kawakami; Shigenori Kadowaki; Akitaka Makiyama; Masahiro Tsuda; Kenro Hirata; Naotoshi Sugimoto; Nozomu Machida; Hiroki Hara; Hidekazu Hirano; Taito Esaki; Yoshito Komatsu; Shuichi Hironaka; Yukari Kobayashi; Kazuhiro Kakimi; Yasutaka Chiba; Narikazu Boku; Ichinosuke Hyodo; Kei Muro

Read Abstract: Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization. © International Society for Disease of the Esophagus – ISDE 2024 | Any unauthorized use or reproduction of the content is prohibited without explicit permission.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software